

## INICHE BORATORIES

CIN:L99999MH1962PLC012451

Regd. Office: "Unichem Bhavan", Prabhat Estate, Off.S.V. Road, Jogeshwari (West), Mumbai - 400 102 Tel. No.: 91 (22) 6688 8333 • Fax. No.: 91 (22) 2678 4391/5198

Website: http://www.unichemlabs.com • E-mail ID.: shares@unichemlabs.com

## STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED STATEMENT OF & HALF YEAR ENDED 30TH SEPTEMBER, 2014. (₹ in Lacs) Half year ended Three months Three months Three month: Half year Accounting Year ended ended ended ended ended **Particulars** 30th Sep'13 30th Jun'14 (Unaudited) (Unaudited) (Audited) (Unaudited) (Unaudited) (Unaudited) **INCOME FROM OPERATIONS** Net Sales/Income from operations (Net of excise duty) 28,850.33 27,494.79 26,618.75 56,345.12 52,839.21 102,892.08 Other Operating Income TOTAL INCOME FROM OPERATIONS (NET) 29,099.09 104,417.50 27,815.18 26,957.12 56,914.27 53,515.00 **EXPENSES** Cost of Material Consumed 6,661.56 16,233.37 13,213.94 27,103.30 8,331.65 7,901.72 Purchases of stock-in-trade 3,671.21 4,138.87 3,321.03 7,810.08 6,831.30 12,758.93 Changes in inventories of finished goods, work-in-progress and stock-in-trade (970.46) (575.07) (562.27) (1,545.53) (1,029.39) (2,758.11) 8 276 72 d) Employee benefits' expense 4.613.71 4.992.60 4.144.91 9.606.31 16.208.87 Depreciation and amortisation expense 2,166.15 847.26 1,097.97 Other expenses 8,830.56 8,273.05 8,370.73 17,103.61 16,115.54 32,991.30 TOTAL EXPENSES 25,578.43 23,033.93 51,129.06 45,574.26 25,550.63 90,570.87 Profit/(Loss) from operations before other income, 3.520.66 7.940.74 finance costs and exceptional items (1-2) 2.264.55 3.923.19 5.785.21 13.846.63 ,283.9 1,074.10 556.7 Profit/(Loss) from ordinary activities before finance costs 4,038.02 4,693.61 2,821.29 9,472.15 and exceptional items (3+4) 6,859.31 18,130.54 Finance costs 56.30 73.33 64.88 129.63 126.55 248.16 Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6) 4,628.73 3,964.69 6,729.68 9,345.60 17,882.38 Exceptional items (Refer Note 5) 4,900.55 2,764.99 Profit/(Loss) from ordinary activities before tax (7+8) 3,964,69 4,628,73 6,729,68 9.345.60 22,782,93 10 11 Tax Expenses 945.00 1,008.00 2,115.00 533.00 1,478.00 5,086.11 Net profit from ordinary activities after tax including 2,231.99 exceptional items (9-10) 3,019.69 3,620.73 5,251.68 7,230.60 17,696.82 Net profit for the period excluding exceptional items Paid up Equity Share Capital (Face Value ₹.2 per share) Reserves & Surplus excluding Revaluation Reserve as per balance **3,620.73** 1,811.73 3,019.69 1,814.07 1,813.15 1,814.07 1,811.73 1,812.55 sheet of previous accounting year. Earning Per Share ( Face Value of ₹. 2/ each) including exceptional items 88.814.17 15 a) Basic - ₹. 2.46 3.33 4.00 5.79 7.99 19.54 Diluted - ₹ 2.45 3.32 3.99 5.77 7.97 19.47 Earning Per Share (Face Value of ₹. 2/ each) excluding exceptional items a) Basic -₹. 2.46 3.33 4.00 5.79 7.99 15.00 b) Diluted - ₹. 14.94 **PART II** PARTICULARS OF SHAREHOLDING Public Shareholding Number of Shares 45,192,850 45,147,026 45,076,051 45,192,850 45,076,051 45,116,776 Percentage of Shareholding Promoters and Promoters group shareholding 49.82% Pledged /Encumbered Number of Shares Percentage of shares (as a % of the total Nil Nil Nil Nil Nil Nil shareholding of promoter and promoter group) Percentage of shares (as a % of the total Nil Nil Nil Nil Nil Nil share capital of the company ) b) Non- encumbered - Number of Shares 45,510,550 45.510.550 45,510,550 45,510,550 45,510,550 45,510,550 100 00% - Percentage of shares ( as a % of the total 100.00% shareholding of promoter and promoter group) - Percentage of shares (as a % of the total share capital of the company) 50.22% 50.18% 50.20% 50.24% 50.18% 50.24% Quarter Ende Particulars 30.09.2014

## Remaining unresolved at the end of the quarter Notes:

PARTI

The above results have been subjected to Limited Review by the Statutory Auditors, reviewed by the Audit Committee and taken on record by the Board of Directors of the Company and the Audit Committee and taken on record by the Board of Directors of the Company and the Audit Committee and taken on record by the Board of Directors of the Company and the Audit Committee and taken on record by the Board of Directors of the Company and the Audit Committee and taken on record by the Board of Directors of the Company and the Audit Committee and taken on record by the Board of Directors of the Company and the Audit Committee and taken on record by the Board of Directors of the Company and the Audit Committee and taken on record by the Board of Directors of the Company and the Audit Committee and taken on record by the Board of Directors of the Company and the Audit Committee and taken on record by the Board of Directors of the Company and the Audit Committee and taken on the Audit Committee and the Audin its meeting held on 18th October 2014.

13

13

Segment Reporting:

INVESTOR COMPLAINTS Pending at the beginning of the quarter Received during the guarter

Disposed of during the quarter

Primary Segment

The Company has only one segment i.e. 'Pharmaceuticals'.

Secondary Segment (By Geographical Segment)

(₹ in Lacs)

Net Sales and Operating Income	Three months ended 30th Sep'14 (Unaudited)	Three months ended 30th Jun'14 (Unaudited)	Three months ended 30th Sep'13 (Unaudited)	Half year ended 30th Sep'14 (Unaudited)	Half year ended 30th Sep'13 (Unaudited)	Accounting Year ended 31st Mar'14 (Audited)
Within India	17,276.73	18,798.62	18,090.25	36,075.35	36,194.01	68,449.28
Outside India	10,538.45	10,300.47	8,866.87	20,838.92	17,320.99	35,968.22
Total	27,815.18	29,099.09	26,957.12	56,914.27	53,515.00	104,417.50

In view of the interwoven / intermix nature of the business and manufacturing facility, other segmental information is not ascertainable.

Other Income includes exchange gain as under:

(₹ in Lacs)

Exchange Difference	Three months ended 30th Sep'14 (Unaudited)	Three months ended 30th Jun'14 (Unaudited)	Three months ended 30th Sep'13 (Unaudited)	Half year ended 30th Sep'14 (Unaudited)	Half year ended 30th Sep'13 (Unaudited)	Accounting Year ended 31st Mar'14 (Audited)
Exchange gain included in Other Income	137.88	140.11	408.01	277.99	930.19	942.51
4 Unaudited Statement of Assets & Liabilities as on 30 09 2014	-					

				(₹ in Lacs)
		Particulars	As at 30th Sept 2014	As at 30th Sept 2013
L	EQI	JITY AND LIABILITIES		
Г		Shareholders' Fund		
		Share Capital	1,814.07	1.811.73
	(b)	Reserve & Surplus	93,876.11	86,786.86
	( - )		95,690.18	88,598.59
	(2)	Share Application Money pending allotment	14.16	-
	(3)	Non Current Liabilities		
	(a)	Long term borrowings	2,385.74	2,548.52
	(b)	Deferred tax liabilities (Net)	4,053.47	4,017.43
	(c)	Long term provisions	1,181.37	1,352.70
			7,620.58	7,918.65
	(4)	Current Liabilities		
	(a)	Short term borrowings	998.33	1,417.97
	(b)	Trade payables	16,834.74	15,777.23
	(c)	Other current liabilities	3,199.12	3,046.00
	(d)	Short -term provisions	345.51	-
			21,377.70	20,241.20
		TAL EQUITY AND LIABILITIES	124,702.62	116,758.44
_		SETS		
	(I)	Non-current assets		
	(a)			
	(i)	Tangible assets	37,565.48	49,747.09
	(ii)		-	1,006.76
	(iii)	Capital wok-in-progress	11,484.85	6,036.53
			49,050,33	56,790.38
	(b)	Non-current Investment	11,672.03	11,169.13
	(c)	Long term loans and advances	4,802.44	1,382.26
	(2)			
		Current Investments	333.33	600.00
	٠,	Inventories	19,762.33	14,531.06
	(c)	Trade receivables	24,002.02	22,965.95
	(d)	Cash & Bank Balances	2,786.38	1,867.15
	(e)	Short term Loans and advances	10,950.69	7,079.81
	(f)	Other current assets	1,343.07	372.70
			59,177.82	47,416.67
	TOT	FAL ASSETS	124,702.62	116,758.44

Exceptional items reported for the previous accounting year ended 31st March 2014 represent profits on sale of Company's manufacturing unit at SEZ, Indore and amortisation of Intangible assets due to change in their estimated useful life.

 $\label{lem:previous} Previous\ years\ figures\ have\ been\ regrouped\ /\ reclassified\ wherever\ necessary.$ 

Place : Mumbai Date : 18<sup>th</sup> October 2014

By Order of the Board For UNICHEM LABORATORIES LIMITED

Sd/-Dr. Prakash A. Mody Chairman & Managing Director